1. Home
  2. PRSO vs XCUR Comparison

PRSO vs XCUR Comparison

Compare PRSO & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRSO

Peraso Inc.

HOLD

Current Price

$0.91

Market Cap

14.4M

Sector

Technology

ML Signal

HOLD

XCUR

Exicure Inc.

HOLD

Current Price

$2.31

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
XCUR
Founded
2008
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.4M
13.7M
IPO Year
2000
2017

Fundamental Metrics

Financial Performance
Metric
PRSO
XCUR
Price
$0.91
$2.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
624.2K
20.3K
Earning Date
05-11-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
81.23
83.37
EPS
N/A
N/A
Revenue
$14,573,000.00
N/A
Revenue This Year
$18.48
N/A
Revenue Next Year
$53.57
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.99
N/A
52 Week Low
$0.77
$1.71
52 Week High
$2.37
$9.50

Technical Indicators

Market Signals
Indicator
PRSO
XCUR
Relative Strength Index (RSI) 42.23 33.63
Support Level $0.81 N/A
Resistance Level $0.95 $3.50
Average True Range (ATR) 0.06 0.35
MACD -0.02 -0.06
Stochastic Oscillator 9.86 34.48

Price Performance

Historical Comparison
PRSO
XCUR

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About XCUR Exicure Inc.

Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Share on Social Networks: